Estrogen receptor-targeted optical imaging of breast cancer cells with near-infrared fluorescent dye

Molecular imaging provides the in vivo characterization of cellular molecular events involved in normal and pathologic processes. With the advent of optical molecular imaging, specific molecules, proteins and genes may be tagged with a luminescent reporter and visualized in small animals. This powerful new tool has pushed in vivo optical imaging to the forefront as it allows for direct determination of drug bio-distribution and uptake kinetics as well as an indicator of biochemical activity and drug efficacy. Although optical imaging encompasses diverse techniques and makes use of various wavelengths of light, a great deal of excitement in molecular research lies in the use of tomographic and fluorescence techniques to image living tissues with near-infrared (NIR) light. Nonionizing, noninvasive near-infrared optical imaging has great potential to become promising alternative for breast cancer detection. Fluorescence spectroscopy studies of human tissue suggest that a variety of lesions show distinct fluorescence spectra compared to those of normal tissue. It has also been shown that exogenous dyes exhibit selective uptake in neoplastic lesions and may offer the best contrast for optical imaging. Use of exogenous agents would provide fluorescent markers, which could serve to detect embedded tumors in the breast. In particular, the ability to monitor the fluorescent yield and lifetime may also enable biochemical specificity if the fluorophore is sensitive to a specific metabolite, such as oxygen. As a first step, we have synthesized and characterized one such NIR fluorescent dye conjugate, which could potentially be used to detect estrogen receptors (ER)[2] . The conjugate was synthesized by ester formation between 17-β estradiol and a hydrophilic derivative of indocyanine green (ICG) cyanine dye, bis-1, 1-(4-sulfobutyl) indotricarbocyanine-5- carboxylic acid, sodium salt. The ester formed was found to have an extra binding ability with the receptor cites as compared to ICG, which was established by the partition coefficient studies. The replacement of the sodium ion in the ester by a larger glucosammonium ion was found to enhance the hydrophilicity and reduce the toxic effect on the cell lines. The excitation and emission peaks for the conjugate were recorded in the NIR region as 750nm and 788nm respectively. The ester was found nontoxic on adenocarcinoma breast cancer cell lines MCF-7/MDA-MB-231. Specific binding and endocytosis of the estrogen-labeled conjugate was studied on the MCF-7 (ER positive) and MDA-MB-231 (ER negative). Conjugate staining of MCF-7 cells showed ~ 4-fold increase in signal intensity compared to MDA-MB- 231. Further, estrogen molecules were found to be specifically localized to the nuclear region of MCF-7 cells, whereas MDA-MB-231 showed plasma membrane staining. This technique offers the potential of noninvasive detection of hormone receptor status in breast cancer cells and would help in decreasing the load of unnecessary biopsies. Here, we have reported the progress made in the development of a novel NIR external contrast agent and the work is in progress to use this conjugate for the molecular based, diagnostic imaging of breast cancer.

[1]  Eva Forssell-Aronsson,et al.  Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide. , 1996, British Journal of Cancer.

[2]  J. Lewis,et al.  Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. , 1999, Journal of medicinal chemistry.

[3]  G. Mengod,et al.  Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. , 1997, International journal of cancer.

[4]  Daniel L. Farkas,et al.  Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies , 1995, Cancer Immunology, Immunotherapy.

[5]  R. Weissleder,et al.  In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.

[6]  J. Haringsma,et al.  The Value of Fluorescence Techniques in Gastrointestinal Endoscopy: Better than the Endoscopist's Eye? I: The European Experience , 1998, Endoscopy.

[7]  S. Achilefu,et al.  Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. , 2000, Investigative radiology.

[8]  D. Evans,et al.  Gut peptide receptor expression in human pancreatic cancers. , 2000, Annals of surgery.

[9]  P. Neuhaus,et al.  Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. , 1996, Gut.

[10]  J. Reubi,et al.  Expression of somatostatin receptors in peritumoral veins of human tumors , 1999, Cancer.

[11]  H. Bergh,et al.  Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. , 1994, Cancer research.

[12]  H Szmacinski,et al.  Synthesis of squaraine-N-hydroxysuccinimide esters and their biological application as long-wavelength fluorescent labels. , 1994, Analytical biochemistry.

[13]  V. Ntziachristos,et al.  Hydrophilic Cyanine Dyes as Contrast Agents for Near-infrared Tumor Imaging: Synthesis, Photophysical Properties and Spectroscopic In vivo Characterization¶ , 2000, Photochemistry and photobiology.

[14]  Dario Neri,et al.  Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform , 1997, Nature Biotechnology.

[15]  H Stepp,et al.  Fluorescence Endoscopy of Gastrointestinal Diseases: Basic Principles, Techniques, and Clinical Experience , 1998, Endoscopy.

[16]  E. Krenning,et al.  Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  H. Stepp,et al.  Detection of colonic dysplasia by light-induced fluorescence endoscopy: a pilot study , 1999, International Journal of Colorectal Disease.

[18]  B. Wiedenmann,et al.  Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy. , 1994, Seminars in oncology.

[19]  J. Reubi.  Relevance of somatostatin receptors and other peptide receptors in pathology , 1997, Endocrine pathology.

[20]  R. Jensen,et al.  Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization. , 1997, The Yale journal of biology and medicine.

[21]  Uday B. Desai,et al.  Non-invasive imaging of breast cancer: synthesis and study of novel near-infrared fluorescent estrogen conjugate , 2005, SPIE BiOS.